Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
about
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501Targeted drugs in small-cell lung cancerGenomic profiling of small-cell lung cancer: the era of targeted therapiesTargeting angiogenesis in small cell lung cancerPhase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.Small cell lung cancer: therapies and targetsChemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Chemotherapy for small cell lung cancer: a comprehensive reviewSmall cell lung cancer: will recent progress lead to improved outcomes?Efficacy and safety of angiogenesis inhibitors in small-cell lung cancerTargeted therapies in small cell lung cancerThe development of targeted therapy in small cell lung cancer.Advances in antiangiogenic treatment of small-cell lung cancer.Research progress in the treatment of small cell lung cancer.Emerging drugs for small cell lung cancer--an update.Management of small cell lung cancer: recent developments for optimal care.To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.Medical treatment of small cell lung cancer: state of the art and new development.Combination of intravitreal bevacizumab and systemic therapy for choroidal metastases from lung cancer: report of two cases and a systematic review of literature.Progress and challenges in the treatment of small cell lung cancer.Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.Treatment update in small-cell lung cancer: from limited to extensive disease.Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Advanced small cell lung cancer (SCLC): new challenges and new expectations.
P2860
Q24658198-99849BA1-85D1-42FD-8D8A-11275CDA7D8BQ26767017-02B530AA-914D-4FF4-9573-C163298AB623Q26826915-8612AA4D-D2C7-4F39-AFDB-C78077616EB6Q28068385-688ABC34-22F7-4BF4-965C-35A14F0E5BD6Q33394192-A39F5A44-1AC6-42AC-B914-C99A8E6CBEF0Q33443519-64C9414B-5A87-4429-B517-391962DD96CCQ34000985-91B88BC4-1900-430F-9A68-D83F2F114003Q34250859-04A54126-AFD2-4B87-A26E-F7AC83DA02C0Q35222202-369D2BB2-6667-4905-BC3B-0AC01B0915FAQ35569379-2F4D6F57-C689-4B38-B5A9-AAC9F7E2F458Q35836257-0F0EA1DF-E004-4C96-8A76-4A31005ECA26Q36207730-A1F27F3C-2F03-4CF5-812C-55738A15993DQ36475811-8DCE1A26-226E-4AF3-BCF7-314028485AEAQ37127932-C3E9688A-CB4F-4AED-9808-69430A2DD890Q37588040-7217F905-321B-4B7B-8053-F7DE9D0AD382Q37604301-FF611374-AE24-4953-AB14-A3A5708EEB26Q37979856-19587AD1-56FD-4B92-BB84-D15C599B5D98Q37987205-B07A10B8-1526-45ED-8787-825065C7E836Q38105006-A6D83FD5-CD7C-44A1-987A-C9BF80D819BDQ38125489-FB5416EA-64B4-4A5C-AA7E-C53C4F9E8015Q38194075-2290A9E6-6B26-4B31-932C-21949B4F7500Q39272825-D67D7B53-70CB-4577-BDB6-C1E896FA9C09Q40901357-79ADA1A5-5A31-4A24-AFBF-37122F9921DCQ41526347-0DC675FC-72AD-475D-8FE0-4714B5906E19Q43939698-8347F77A-1E8F-4BBD-9F7A-7C5F0ED03646Q45304925-D1063481-530D-44DA-8A6C-500CA1D576C2Q46659724-ACFAE36A-2F3E-4F77-8AB3-7836A5F6943FQ48286025-4A60ECB0-FCC3-46B0-9866-3C0EECF0019BQ48374393-C448ECC7-18C9-45EA-B4F1-F44C07F24652Q54977232-965562FF-9A26-4BA5-A265-C20388617E09
P2860
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II trial of irinotecan, ...... -stage small-cell lung cancer.
@ast
Phase II trial of irinotecan, ...... -stage small-cell lung cancer.
@en
type
label
Phase II trial of irinotecan, ...... -stage small-cell lung cancer.
@ast
Phase II trial of irinotecan, ...... -stage small-cell lung cancer.
@en
prefLabel
Phase II trial of irinotecan, ...... -stage small-cell lung cancer.
@ast
Phase II trial of irinotecan, ...... -stage small-cell lung cancer.
@en
P2093
P1476
Phase II trial of irinotecan, ...... -stage small-cell lung cancer.
@en
P2093
Cindy Farley
David R Spigel
Denise A Yardley
F Anthony Greco
Howard A Burris
John D Zubkus
Patrick B Murphy
Ruben A Saez
P304
P356
10.1097/JTO.0B013E3181BBC540
P577
2009-12-01T00:00:00Z